=
Cancer staging system 9 . Patients were classified into the three prognostic risk 111 groups defined by D'Amico 1 . Patient and tumor characteristics are presented in 112 Table 1 . 113 114
Treatment characteristics 115 116
The target volume comprised the prostate only in the low risk group (16%), the 117 prostate and the seminal vesicles in the other risk groups. The pelvic lymph nodes 118
were not treated in the two randomized studies, but may have been treated for high 119 risk patients of the two institutions (not treated in the randomized study) (9%). The 120 median total dose of the prostate was 70 Gy (ranging from 65 Gy to 80 Gy), the 121 seminal vesicles receiving 46 Gy, and the pelvic lymph nodes also 46 Gy, if treated. 122 Dose per fraction was 2 Gy/day, 5 fractions/week for 69% of patients, or 2.5 Gy/day, 123 4 fractions/week for 31% of patients. 124
The radiation technique was 3D conformational for the vast majority of patients (85%) 125 and 2D for 15% of the patients, depending on the treatment period. Intensity 126 Modulated RT (IMRT) and Image Guided RT (IGRT) have been more recently used 127 in patients receiving 80 Gy. Among the 41% of the patients having received 80 Gy, 128 the technique was a standard 3D conformal RT for 63%, IMRT only for 18% and 129
IMRT combined with IGRT in 19%. 130
The 3D radiation technique was carried out following the French GETUG group 131 recommendations, as previously reported 7 . Patients underwent simulation and 132 treatment in the supine position. Target volume and organs at risk (bladder, rectum 133 and femoral heads) were delineated on CT slices. A bladder wall was generated with 134 a thickness of 7 mm from the external manually-delineated bladder contour according= GETUG recommandations. The planning target volume (PTV) was calculated by 136 adding a 10-mm margin in all directions except in the posterior where a 5-mm margin 137 was considered. The dose-volume histogram had to respect the GETUG constraints 138 7 . The following bladder dosimetric data were analyzed: volume of the bladder wall, 139
Dmax (maximal dose received in the bladder), D25 (minimal dose received in 25% of 140 the bladder wall) and D50 (minimal dose received in 50% of the bladder wall). 141
Androgen deprivation therapy was given to 23% of the patients, all presenting a high 142 risk cancer. 143
Details of treatment characteristics are presented in Table 1 . 144 145
Follow up and toxicity grading 146 147
According to the protocol of surveillance, patients were evaluated every three months 148 for a year and every 6 months thereafter Late urinary toxicity was defined as events 149 occurring more than six months after the beginning of RT. To determine the severity 150 and incidence of main late urinary complaints, records were prospectively extracted 151 from trials database or retrospectively from physicians' reports, at each follow-up 152 visit. Urinary complaints were classified according to the LENTSOMA morbidity 153 scoring system into four categories of symptoms: urinary frequency, dysuria, 154 incontinence and hematuria ( The data-recording modality (prospective versus retrospective collection) was 171 verified as having no significant impact on the risk of toxicity. 172
The Kaplan-Meier method was used to calculate cumulative incidences of late 173 urinary toxicity events (! grade 2). The differences between the survival curves 174
were assessed using the log-rank test. Relationships between late urinary toxicity 175 and patient, tumor or treatment parameters were first analyzed using Cox 176 proportional hazard regression at univariate level. Multivariate analyses, including 177 covariates statistically significant in univariate analysis, were carried out using the 178 Cox proportional hazards model. The 5-year late urinary toxicity events were 179 analyzed using logistic regression at univariate and multivariate levels. A p-value 180 " 0.05 was considered statistically significant. Nomograms to predict 5-year late 181 urinary toxicity and specific symptoms were built up according to the logistic 182 model. To assess nomogram performance, a nonparametric fit of the predicted 183 probability as regards the actual observed probability was made for each 184 nomogram. The analyses were performed using the SPSS V18 (Chicago, IL) and 185 = R with the rms package. Non-parametric tests were used to compare the 186 distribution of the parameters between different groups of treatment. 187 188
Results 189 190
The median follow-up was 61 months (range 6-206) . hematuria, dysuria and urinary incontinence were: 15% (95%CI:12%-18%) and 24% 200 (95%CI:19%-29%), 10% (95%CI: 8%-12%) and 15% (95%CI:11%-19%), 5% (95% 201 CI: 4-6%) and 8% (95%CI:5%-11%), 3% (95%CI: 2%-4%) and 8% (95%CI:4%-12%), 202 and 1% (95%CI: 0%-2%) and 2% (95%CI:0%-4%), respectively. by the bladder (Table 3) . Nomogram including pre-treament factors to predict 5-year 213 risk of global late urinary toxicity (and its calibration plot) is presented in Figure 2 . 214
The 5-year risk of urinary frequency was related to total dose (RR=1.07) and 215 diabetes (RR=4). For dysuria, the total dose was the only significant factor (RR=1.1) 216 (Table 3) 
Discussion 221
We showed that the incidence of late urinary toxicity symptoms continuously 222 increases after RT, reaching a rate of 24% and 7% at 10 years, for more than grade 223 2 and grade 3 urinary toxicity, respectively. These rates appear relatively similar to 224 those previously observed after RT 7 . Urinary toxicity events may occur late after RT, 225 later than those observed for late gastro-intestinal toxicity which generally reaches a 226 plateau at three years after RT 10 . A longer follow-up is consequently required to 227 properly estimate late urinary toxicity 10 . Comparing the risk of urinary toxicity after 228 different treatments should therefore carefully consider the same follow-up. Late 229 urinary toxicity symptoms are mainly characterized by urinary frequency (50% of all 230 events) and, to a lesser extent, by dysuria and hematuria. Incontinence is very rare 231 (<2% at 10 years). 232
We identified age, diabetes and anticoagulant treatment as factors increasing the risk 233 of late urinary toxicity by multivariate analysis. Diabetes has already been reported 234 as a strong predictor of late urinary toxicity in prostate cancer radiotherapy 11 . The 235 = fact that anticoagulation or antiplatelet agents increase the risk of late urinary toxicity 236 after prostate cancer radiotherapy has rarely been reported, even if this association 237 concerns the risk of late rectal toxicity 12, 13 . However, anticoagulation has been 238 already associated with gross hematuria in the whole population and could be an 239 independent risk factor of urinary complaints whatever a radiation is performed. Age 240 and diabetes have been previously associated with urinary side effects after radical 241 prostatectomy, especially urinary incontinence 14, 15 . Thus, their implications in urinary 242 toxicity after RT should not be underestimated in treatment decision. 243
We found a strong dose-effect relationship in urinary toxicity (global toxicity, urinary 244 frequency and dysuria). Most of the randomized studies comparing a "standard" dose 245 (68 to 70 Gy) to a higher one (76 to 80 Gy) did not demonstrate such a significant 246 increase in late urinary toxicity [16] [17] [18] [19] . However, in a large group of patients who 247 received a dose escalation with 3D-CRT/IMRT, Zelefsky et al reported a significant 248 increase of genitourinary (GU) toxicities after 10 years in patients who received 249 higher doses 20 . More recently, the GETUG 06 randomized trial reported such an 250 increase, when escalating the dose from 70 Gy to 80 Gy 7 . These differences can be 251 explained by several reasons. The first one is the lack of follow-up. Indeed, the initial 252 MDACC report that compared 78Gy to 70Gy did not show a significant difference in 253 late GI toxicity, while it was found with a longer follow-up 16 . Secondly, studies might 254 be different in terms of their treatment scheme (dose, target volume, technique), 255 patient characteristics and grading scale. Finally, urinary toxicity might be more 256 related to patient risk factors than dose parameters. The lack of correlation between 257 dose distribution (dose-volume histogram) and urinary toxicity may also be due to the 258 large bladder volume variation occurring at the planning stage and at the different IGRT still do not allow for the preservation of this area. A recent non-randomized 271 study of Zelefsky et al reported however that, with a median follow-up of 2.8 years 272
and a high dose (86.4 Gy) delivered to the prostate by IMRT, patients treated with 273 IGRT (using fiducials) experienced significantly less urinary toxicity than non-IGRT 274 treated patients 25 . 275
Based on this predictive factors, we propose the first nomograms to predict late 276 urinary toxicity after radiation therapy. Indeed, many treatments now provide long 277 term survival and the decision of the patient concerning his own treatment is mainly 278 based on expected side effects. These nomograms have been built up according to 279 the pre-treatment parameters, available before any CT simulation, in order to help 280 physician and patient in the decision concerning the different prostate cancer 281 treatments. Consequently, we believe that the corresponding nomograms concerning 282 toxicity after radical prostatectomy should be proposed. 283
One limitation of our study is that both prospective and retrospective data (from 2= institutions) were used to assess our nomograms. However, the effect of data being 285 retrospectively collected was not found to significantly impact on toxicity risk. 286
Furthermore, a large number of patients was necessary to identify a maximum 287 number of reliable toxicity predictors. Finally, nomogram performance has been 288 validated within our series but should be also confirmed using external data. 289 290
Conclusions 291 292
We were able to identify several parameters increasing the risk of urinary toxicity 293 after prostate cancer radiotherapy. The first nomograms to predict global late urinary 294 toxicity and corresponding symptoms were generated, resulting in new tools for 295 patient management and treatment decision, particularly between RT and surgery. 
